Clinical trials: First Pregnancy
Wheezing, LRTI
Protecting Preterm Infants From Respiratory Tract Infections and Wheeze by Using Bacterial Lysates.
The primary objective of this study is to reduce respiratory tract infections and wheezing in moderate-late preterms in the first years of life by bacterial lysate administration.
- Conditions
- Wheezing, LRTI, Premature
- Trial name
- PROTEA (NCT05063149)
- Testing
- Broncho-Vaxom
- Where
- Netherlands
- Volunteers
- 500 people
- Sponsor
- Franciscus Gasthuis
Missed Abortion
Letrozole Pretreatment With Misoprostol Induction of Abortion in First Trimester Missed Abortion
this study will compare the efficacy of using letrozole pre treatment before misoprostol versus using misoprostol only in the induction of first trimester missed abortion.
- Trial name
- NCT04590482
- Testing
- letrozole
- Volunteers
- 110 people, healthy volunteers welcome
- Sponsor
- Shereen Rady Abou El-fetouh
Nausea Gravidarum, Anxiety
Anxiety in Relation to Nausea and Vomiting in Pregnancy
The goal of this observational study is to learn more about the relation between anxiety (assessed by GAD-7 questionnaire) and the nausea and vomiting in pregnancy (objectively measured by PUQE score).
- Trial name
- NCT06059794
- Testing
- PUQE score, GAD-7
- Where
- Egypt
- Volunteers
- 102 people
- Sponsor
- Ain Shams Maternity Hospital
Bladder Cancer
Evaluation of ATO-101™ in Patients With Non-Muscle-Invasive Bladder Cancer (PERSEVERANCE EU)
Non-Muscle-Invasive Bladder cancer (NMIBC) tumours often recur despite TransUrethral Resection of Bladder (TURB) and Bacillus Calmette-Guerin (BCG) intravesical instillations, and have no effective conservative treatment options.
- Trial name
- PERSEVERANCE (NCT07260162)
- Testing
- ATO-101™
- Where
- France
- Volunteers
- 24 people
- Sponsor
- Institut Cancerologie de l'Ouest
Stress Urinary Incontinence
A Phase 2a Study To Evaluate VMB-100 In Females With Stress Urinary Incontinence
The study drug VMB-100 is an mRNA encoding for IGF-1. It is administered by injection into the urethra sphincter, and taken up by the muscle cells.
- Trial name
- NCT06247241
- Testing
- VMB-100
- Sponsor
- Versameb AG
Advanced Solid Cancer, Metastatic Solid Tumor
Study of SYN818 for the Treatment of Advanced or Metastatic Solid Tumors
This interventional study will evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics and preliminary efficacy of SYN818 as monotherapy in adult patients with advanced solid tumors
- Conditions
- Advanced Solid Cancer, Metastatic Solid Tumor, Ovarian Cancer, Breast Cancer
- Trial name
- NCT06666270
- Testing
- SYN818
- Where
- 2 sites in China
- Volunteers
- 30 people
- Sponsor
- Hangzhou SynRx Therapeutics Biomedical Technology Co., Ltd
Birth, First, Birth Outcome, Adverse
Reducing Turkey High Cesarean Section Rates
Considering the increasing rates of cesarean delivery in Turkey, we aimed to research the impact of antenatal education on pregnancy, the childbirth process, the cesarean section rate, and the postpartum period through a…
- Conditions
- Birth, First, Birth Outcome, Adverse, Breast Feeding
- Trial name
- NCT07799545
- Testing
- Antenatal education
- Where
- Turkey (Türkiye)
- Volunteers
- 120 people, healthy volunteers welcome
- Sponsor
- Saglik Bilimleri Universitesi
Clear Cell Sarcoma of the Kidney, Recurrent Renal Cell Carcinoma
Dalteparin and Sunitinib Malate as First-Line Therapy in Treating Patients With Kidney Cancer That is Metastatic or Cannot Be Removed by Surgery
This phase I trial studies the side effects and best dose of dalteparin when given together with sunitinib malate in treating patients with kidney cancer that has spread to other parts of the body or cannot be removed by surgery.
- Conditions
- Clear Cell Sarcoma of the Kidney, Recurrent Renal Cell Carcinoma, Stage III Renal Cell Cancer, Stage IV Renal Cell Cancer
- Trial name
- NCT01061411
- Testing
- Dalteparin, Pharmacological Study, Sunitinib Malate
- Where
- 4 sites in United States, Netherlands
- Volunteers
- 16 people
- Sponsor
- Roswell Park Cancer Institute
Non-muscle-invasive Bladder Cancer
OH2 Oncolytic Viral Therapy in Non-Muscle-Invasive Bladder Cancer
This phase Ⅰb/Ⅱ study evaluates the safety and efficacy of OH2 for adjuvant therapy in non-muscle-invasive bladder cancer after first-line prophylactic intravesical instillation therapy.
- Trial name
- NCT05232136
- Testing
- OH2 injection
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Binhui Biopharmaceutical Co., Ltd.
Abortion in First Trimester
Transcutaneous Electrical Nerve Stimulation (TENS) for Pain Management With Medication Abortion Through 70 Days' Gestation
This is a double-blinded, randomized, placebo-controlled trial evaluating the use of High-frequency Transcutaneous Electrical Nerve Stimulation (HfTENS) compared to sham TENS for pain control during medication abortion with…
- Trial name
- NCT03925129
- Testing
- high frequency TENS treatment
- Where
- United States
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Planned Parenthood of Greater New York
Preterm Birth
Initial Oxygen Concentration at Birth in Late-Preterm Infants
This study is aims to examine the best amount of oxygen to give preterm babies (born between 32 and 35 weeks) right after birth.
- Trial name
- OXY-PREEM (NCT07315594)
- Testing
- 60% Oxygen Group - Infants will start in 60% oxygen, 30% Oxygen Group - Infants will start in 30% oxygen
- Where
- Canada
- Volunteers
- 1,520 people
- Sponsor
- University of Alberta
Renal Cell Carcinoma
Study to Evaluate the Efficacy and Safety of Pembrolizumab (MK-3475) in Combination With Axitinib Versus Sunitinib Monotherapy in Participants With Renal Cell Carcinoma (MK-3475-426/KEYNOTE-426)
The purpose of this study is to evaluate the efficacy and safety of pembrolizumab (MK-3475) in combination with axitinib versus sunitinib monotherapy as a first-line treatment for participants with advanced/metastatic renal cell…
- Trial name
- NCT02853331
- Testing
- Pembrolizumab, Axitinib, Sunitinib
- Volunteers
- 861 people
- Sponsor
- Merck Sharp & Dohme LLC
Kidney Diseases, Diabetic Nephropathies
First-In-Human Study of GFB-024 in Healthy Overweight and Obese Participants, and Participants With Type 2 Diabetes
GFB-024 is intended for use in patients with kidney disease such as diabetic nephropathy. This study is the first time GFB-024 has been used in humans.
- Conditions
- Kidney Diseases, Diabetic Nephropathies, Diabetes Complications, Diabetes Mellitus
- Trial name
- NCT04880291
- Testing
- GFB-024
- Where
- United States
- Volunteers
- 39 people, healthy volunteers welcome
- Sponsor
- Goldfinch Bio, Inc.
Renal Cell Carcinoma
A First-in-Human Study of BMS-986506 in Participants With Advanced Clear Cell Renal Cell Carcinoma (ccRCC)
This is a first-in-human study of BMS-986506 in participants with advanced Clear Cell Renal Cell Carcinoma (ccRCC). The primary objective of this study is to find out if BMS-986506 is safe and can be tolerated when taken alone or…
- Trial name
- NCT07195682
- Testing
- BMS-986506, Pumitamig, Ipilimumab
- Where
- 11 sites in United States, Canada and 3 more
- Volunteers
- 281 people
- Sponsor
- Bristol-Myers Squibb
Lung Cancer, Colon Cancer
A Study of PHN-010 in Patients With Advanced Solid Tumors
This first-in-human study will evaluate safety, tolerability, anti-tumor activity, immunogenicity, pharmacokinetics and pharmacodynamics of PHN-010, a novel antibody-drug conjugate (ADC), in patients with advanced solid tumors.
- Conditions
- Lung Cancer, Colon Cancer, Endometrial Cancer, Ovarian Cancer
- Trial name
- NCT06457997
- Testing
- PHN-010
- Where
- 8 sites in United States
- Volunteers
- 26 people
- Sponsor
- Pheon Therapeutics
Non-small Cell Lung Cancer(NSCLC), Head and Neck Squamous Cell Carcinoma(HNSCC)
Study to Evaluate LB-LR1109, Administered Alone for the Treatment of Solid Tumor and in Combination With Atezolizumab for the Treatment of NSCLC
This is a Phase 1a/1b, first-in-human (FIH), multi-center, open-label, non-randomized, dose escalation study, designed to determine the Maximum tolerated dose(MTD)/Recommended Phase 2 dose (RP2D) and to evaluate safety…
- Conditions
- Non-small Cell Lung Cancer(NSCLC), Head and Neck Squamous Cell Carcinoma(HNSCC), Renal Cell Carcinoma(RCC), Urothelial Carcinoma
- Trial name
- LB-LR1109 (NCT06332755)
- Testing
- Phase 1a: LB-LR1109, Phase 1b: LB-LR1109 and Atezolizumab
- Where
- United States
- Volunteers
- 76 people
- Sponsor
- LG Chem
Stage III Ovarian Cancer, Stage IV Ovarian Cancer
HOT: HIPEC in Ovarian Cancer as Initial Treatment
Community hospital based phase II (prospective randomized) study to evaluate the toxicity of cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) in newly diagnosed, otherwise untreated, advanced…
- Conditions
- Stage III Ovarian Cancer, Stage IV Ovarian Cancer, Epithelial Ovarian Cancer, Fallopian Tube Cancer
- Trial name
- CRS/HIPEC (NCT02124421)
- Testing
- Cytoreductive Surgery (CRS), Adjuvant Chemotherapy, Questionnaire
- Where
- United States
- Volunteers
- 32 people
- Sponsor
- Mercy Medical Center
Epithelial Ovarian Cancer
Intraperitoneal (IP) Cisplatin Given With Paclitaxel to Treat Epithelial Ovarian Cancer
The purpose of this study is to determine whether intraperitoneal (IP) Cisplatin combined with intravenous (IV) Paclitaxel is well tolerated in women with epithelial ovarian cancer who have had neoadjuvant chemotherapy followed…
- Trial name
- OVHM-01 (NCT00889733)
- Testing
- Intraperitoneal (IP) Cisplatin
- Where
- Canada
- Volunteers
- 9 people
- Sponsor
- University Health Network, Toronto
Advanced Solid Tumor, BRAF V600 Mutation
Safety and Tolerability of ABM-1310 in Patients With Advanced Solid Tumors
This is a Phase I, First-In-Human, open label, dose escalation and dose expansion study to evaluate the safety, tolerability, pharmacokinetics, and preliminary anti-cancer activity of ABM-1310 in adult patients with locally…
- Trial name
- NCT04190628
- Testing
- ABM-1310, Cobimetinib
- Where
- 8 sites in United States
- Volunteers
- 53 people
- Sponsor
- ABM Therapeutics Corporation
Urinary Bladder Neoplasms
Gemcitabine, Cisplatin, Plus Lenalidomide as First-line Therapy for Patients With Metastatic Urothelial Carcinoma
The primary objectives of this study are (Phase 1) to determine in subjects with unresectable or metastatic bladder cancer who have never had chemotherapy, the dose of lenalidomide that is well-tolerated when given in combination…
- Trial name
- NCT01342172
- Testing
- Lenalidomide
- Where
- 3 sites in United States
- Volunteers
- 9 people
- Sponsor
- Icahn School of Medicine at Mount Sinai
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.